Our latest research report titled "T Cell Therapy Market Forecast (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis ? by Modality, Therapy Type, and Indication" indicates that the T cell therapy market was valued at approximately US$ 2,754.00 million in 2022, with projections suggesting it will grow to around US$ 9,035.01 million by 2030. This growth represents a compound annual growth rate (CAGR) of 16.0% from 2020 to 2030.
T cell therapy is emerging as one of the most effective cancer treatment modalities, with a steady increase in both pre-clinical and clinical research aimed at expanding its applications. The interest in CAR T cell therapy has surged among oncologists and researchers alike. The escalating global cancer burden, coupled with a rising number of approvals for T cell therapies, is propelling the expansion of the T cell therapy market. Furthermore, the growing number of CAR T-cell therapies undergoing clinical trials is anticipated to further stimulate market growth in the years ahead.
The current environment for CAR T-cell therapies is highly encouraging, characterized by numerous drug approvals, a robust pipeline, and a multitude of ongoing clinical trials. Major pharmaceutical companies are actively engaged in advancing their CAR T-cell therapy pipelines, which bodes well for future growth in this competitive sector.
- In November 2022, a Collaborative Development Program Agreement (CDPA) was established between Peter MacCallum Cancer Centre and Cartherics Pty Ltd to develop Cartherics' proprietary autologous CAR T cell therapy (CTH-001) aimed at treating cutaneous T-cell lymphoma (CTCL). This collaboration focuses on establishing clinical-scale manufacturing of CTH-001 and initiating a Phase I clinical trial, which will initially enroll six patients suffering from refractory CTCL.
- JW Therapeutics is developing JWCAR029, a CAR T cell product targeting CD19, intended for the treatment of advanced lymphoma and leukemia. Currently in Phase II development, JWCAR029 is being investigated for its efficacy against B-cell malignancies, particularly relapsed and refractory diffuse large B-cell lymphoma (DLBCL).
- Gilead Sciences is exploring KTE-X19, an autologous CD19 CAR T-cell therapy. This drug is produced using the XLP process, which includes T-cell selection and lymphocyte enrichment, necessary for certain B-cell malignancies. KTE-X19 is currently undergoing Phase II clinical trials for both adult and pediatric acute lymphoblastic leukemia. The FDA has already approved Brexucabtagene autoleucel (formerly KTE-X19; Tecartus) for adult patients with relapsed or refractory mantle cell lymphoma (MCL).
- The ZUMA-3 study is a Phase 1/2 trial assessing KTE-X19, an autologous anti-CD19 CAR T-cell therapy, in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL).
- Descartes-11, an mRNA CAR T-cell therapy, has progressed to a Phase II clinical trial for newly diagnosed, high-risk multiple myeloma (MM) patients. This therapy transiently expresses CAR T-cell molecules, potentially mitigating some of the typical toxicities associated with CAR T-cell treatments. A prior Phase I study involving 18 patients demonstrated no signs of cytokine release syndrome or neurotoxic adverse events, which are commonly linked to CAR T-cell therapies.
These developments in CAR T-cell therapy pipelines signify a notable trend within the T cell therapy market.
Insights on T Cell Therapy Market by Modality
The T cell therapy market is categorized by modality into research and commercialized segments. In 2022, the commercialized segment dominated the market share and is projected to experience the fastest growth during the forecast period. This growth is driven by an increase in product launches and heightened awareness regarding the advantages of T cell therapy in cancer treatment.
Insights on T Cell Therapy Market by Therapy Type
When categorized by therapy type, the T cell therapy market is divided into CAR T cell therapy and T cell receptor (TCR)-based therapies. The CAR T cell therapy segment held a significant market share in 2022 and is expected to continue growing at a substantial rate throughout the forecast period. In CAR T cell therapy, T cells are extracted from patients and bioengineered to express chimeric antigen receptors (CARs) that can recognize and bind to tumor cells. Companies in the CAR T cell segment are engaging in strategic initiatives such as collaborations, expansions, agreements, partnerships, and new product launches, which are driving the growth of the T cell therapy market. For example, in 2022, the FDA approved CARVYKTI, developed by Janssen Biotech, Inc. This CAR-T therapy (ciltacabtagene autoleucel) is designed for adult patients with multiple myeloma who have experienced relapses or refractory conditions after four or more prior treatment lines, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Key sources utilized in the preparation of the T cell therapy market report include the World Health Organization (WHO), the European Cancer Patient Coalition, and the National Cancer Institute, among others.